At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MPLT MapLight Therapeutics, Inc.
Trading 07-31 14:19:23 EDT
13.52
-0.51
-3.67%
High14.81Low13.19Vol705.72K
Open14.42D1 Closing14.03Amplitude11.55%
Mkt Cap612.85MTradable Cap148.35MTotal Shares45.35M
T/O9.77MT/O Rate6.43%Tradable Shares10.98M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Catalyst4 Reports $13.84 Million MapLight Therapeutics Common Share Purchase
Reuters  ·  07-31 06:40
Catalyst4 Reports $13.84 Million MapLight Therapeutics Common Share Purchase
MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies
TIPRANKS  ·  07-30 23:26
MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies
Maplight Therapeutics Director Troy Cox Reports Purchase of 15,620 Shares Worth $148,702.4
Reuters  ·  07-29 09:15
Maplight Therapeutics Director Troy Cox Reports Purchase of 15,620 Shares Worth $148,702.4
MapLight Therapeutics price target lowered to $24 from $43 at Canaccord
TIPRANKS  ·  07-28
MapLight Therapeutics price target lowered to $24 from $43 at Canaccord
MapLight downgraded to Equal Weight from Overweight at Morgan Stanley
TIPRANKS  ·  07-28
MapLight downgraded to Equal Weight from Overweight at Morgan Stanley
MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  07-28
MapLight Therapeutics is Maintained at Buy by HC Wainwright & Co.
U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit
Reuters  ·  07-28
U.S. Research Roundup- BioLife Solutions, Gossamer Bio, Intuit
Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34
THOMSON REUTERS  ·  07-28
Maplight Therapeutics Inc : Jefferies Cuts Target Price to $25 from $34
Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)
TIPRANKS  ·  07-28
Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)
MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge
Reuters  ·  07-27
MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge
Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug
THOMSON REUTERS  ·  07-27
Maplight Therapeutics Shares Drop 55.7% Premarket After Co Announces Mid-Stage Trial Results for Schizophrenia Drug
Top Premarket Decliners
MT Newswires Live  ·  07-27
Top Premarket Decliners
MapLight Therapeutics announces topline results from ZEPHYR trial
TIPRANKS  ·  07-27
MapLight Therapeutics announces topline results from ZEPHYR trial
MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia
Reuters  ·  07-27
MapLight Says Phase 2 Zephyr Trial Shows Ml-007c-ma Cuts PANSS Score in Schizophrenia
Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2
THOMSON REUTERS  ·  07-27
Maplight Therapeutics - to Proceed with Additional Registrational Trial and Engage FDA at End-of-Phase 2
Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint
THOMSON REUTERS  ·  07-27
Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint
Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia
THOMSON REUTERS  ·  07-27
Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia
Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events
THOMSON REUTERS  ·  07-27
Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events
Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial
THOMSON REUTERS  ·  07-27
Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
GlobeNewswire  ·  07-27
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

Introduction

Company Name.
MapLight Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--